Matthew L. Sherman net worth and biography

Matthew Sherman Biography and Net Worth

Matthew L. Sherman, is Executive Vice President and Chief Medical Officer of Deciphera Pharmaceuticals. Dr. Sherman joined Deciphera in 2019 and brings over 25 years of experience as a physician-scientist in clinical drug development in oncology and hematology at leading biotechnology and pharmaceutical companies. Prior to joining Deciphera, Dr. Sherman served as Chief Medical Officer of Acceleron Pharma, Inc., Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals (now Madrigal Pharmaceuticals) and spent over a decade at Wyeth-Ayerst Research/Genetics Institute, where he led the successful submission, positive Oncologic Drug Advisory Committee recommendation, and FDA approval for the first antibody immune-drug conjugate for acute myeloid leukemia. He currently serves as a director of Pieris Pharmaceuticals and is on the Board of Advisors and Alumni Council at the Geisel School of Medicine at Dartmouth. Dr. Sherman is board certified in Internal Medicine and Medical Oncology and has held various academic and teaching positions at Harvard Medical School with corresponding clinical appointments at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston. Dr. Sherman received a S.B. in Chemistry from the Massachusetts Institute of Technology and a M.D. from Dartmouth Medical School. He completed his internal medicine residency at Georgetown University Medical Center and fellowship in Medical Oncology at the Dana-Farber Cancer Institute.

What is Matthew L. Sherman's net worth?: The estimated net worth of Matthew L. Sherman is at least $2.41 million as of January 16th, 2024. Dr. Sherman owns 94,079 shares of Deciphera Pharmaceuticals stock worth more than $2,407,482 as of December 16th. This net worth evaluation does not reflect any other investments that Dr. Sherman may own. Additionally, Dr. Sherman receives a salary of $865,620.00 as EVP at Deciphera Pharmaceuticals. Learn More about Matthew L. Sherman's net worth.
How old is Matthew L. Sherman?: Dr. Sherman is currently 68 years old. There are 5 older executives and no younger executives at Deciphera Pharmaceuticals. Learn More on Matthew L. Sherman's age.
What is Matthew L. Sherman's salary?: As the EVP of Deciphera Pharmaceuticals, Inc., Dr. Sherman earns $865,620.00 per year. The highest earning executive at Deciphera Pharmaceuticals is Mr. Steven L. Hoerter, President, CEO & Director, who commands a salary of $1,240,000.00 per year. Learn More on Matthew L. Sherman's salary.
How do I contact Matthew L. Sherman?: The corporate mailing address for Dr. Sherman and other Deciphera Pharmaceuticals executives is 200 SMITH STREET, Waltham MA, 02451. Deciphera Pharmaceuticals can also be reached via phone at (781) 209-6400 and via email at [email protected]. Learn More on Matthew L. Sherman's contact information.
Has Matthew L. Sherman been buying or selling shares of Deciphera Pharmaceuticals?: Matthew L. Sherman has not been actively trading shares of Deciphera Pharmaceuticals in the last ninety days. Most recently, Matthew L. Sherman sold 2,435 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $14.47, for a transaction totalling $35,234.45. Following the completion of the sale, the executive vice president now directly owns 94,079 shares of the company's stock, valued at $1,361,323.13. Learn More on Matthew L. Sherman's trading history.
Who are Deciphera Pharmaceuticals' active insiders?: Deciphera Pharmaceuticals' insider roster includes James Bristol (Director), Daniel Flynn (Insider), Thomas Kelly (CFO), Matthew Sherman (EVP), and Michael Taylor (Director). Learn More on Deciphera Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Deciphera Pharmaceuticals?: In the last year, insiders at the sold shares 2 times. They sold a total of 4,059 shares worth more than $58,733.73. The most recent insider tranaction occured on January, 16th when EVP Matthew L Sherman sold 2,435 shares worth more than $35,234.45. Insiders at Deciphera Pharmaceuticals own 4.7% of the company. Learn More about insider trades at Deciphera Pharmaceuticals.
Information on this page was last updated on 1/16/2024.

Matthew L. Sherman Insider Trading History at Deciphera Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2024	Sell	2,435	$14.47	$35,234.45	94,079
10/30/2023	Sell	2,360	$12.02	$28,367.20	90,628
10/2/2023	Sell	2,942	$12.68	$37,304.56	84,744
6/16/2023	Sell	1,655	$14.40	$23,832.00	87,686
2/16/2023	Sell	971	$15.10	$14,662.10	88,145
10/3/2022	Sell	2,587	$18.73	$48,454.51	74,297
6/16/2022	Sell	1,768	$10.75	$19,006.00	76,884
2/16/2022	Sell	984	$9.05	$8,905.20
10/4/2021	Sell	2,659	$33.17	$88,199.03

Matthew L. Sherman Buying and Selling Activity at Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $25.59

$25.59

50 Day Range

MA: $25.59

$25.55

$25.59

2 Week Range

Now: $25.59

$9.90

$25.61

Volume

600 shs

Average Volume

1,292,551 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Altcoin season moves fast, and those who hesitate are left behind. The window is closing.

>> Register for the Workshop Now

Matthew Sherman Biography and Net Worth

What is Matthew L. Sherman's net worth?

How old is Matthew L. Sherman?

What is Matthew L. Sherman's salary?

How do I contact Matthew L. Sherman?

Has Matthew L. Sherman been buying or selling shares of Deciphera Pharmaceuticals?

Who are Deciphera Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Deciphera Pharmaceuticals?